KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $18,798 | -11.4% | 1,952 | -17.2% | 0.00% | – |
Q2 2023 | $21,213 | +14.5% | 2,357 | 0.0% | 0.00% | – |
Q1 2023 | $18,526 | +16.3% | 2,357 | 0.0% | 0.00% | – |
Q4 2022 | $15,933 | -53.1% | 2,357 | 0.0% | 0.00% | – |
Q3 2022 | $34,000 | +70.0% | 2,357 | +14.8% | 0.00% | – |
Q2 2022 | $20,000 | -50.0% | 2,053 | -26.0% | 0.00% | – |
Q1 2022 | $40,000 | +8.1% | 2,773 | 0.0% | 0.00% | – |
Q4 2021 | $37,000 | -11.9% | 2,773 | +13.1% | 0.00% | – |
Q3 2021 | $42,000 | -28.8% | 2,452 | 0.0% | 0.00% | – |
Q2 2021 | $59,000 | +37.2% | 2,452 | +47.2% | 0.00% | – |
Q1 2021 | $43,000 | +72.0% | 1,666 | +26.4% | 0.00% | – |
Q4 2020 | $25,000 | +47.1% | 1,318 | 0.0% | 0.00% | – |
Q3 2020 | $17,000 | -19.0% | 1,318 | -24.1% | 0.00% | – |
Q2 2020 | $21,000 | +31.2% | 1,736 | -17.3% | 0.00% | – |
Q1 2020 | $16,000 | -60.0% | 2,099 | -13.3% | 0.00% | – |
Q4 2019 | $40,000 | +73.9% | 2,422 | +24.6% | 0.00% | – |
Q3 2019 | $23,000 | -46.5% | 1,944 | 0.0% | 0.00% | – |
Q2 2019 | $43,000 | – | 1,944 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |